Owlet (OWLT) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
5 Mar, 2026Executive summary
Achieved record FY2025 revenue of $105.7 million, gross margin of 50.6%, and adjusted EBITDA of $2.0 million, marking the strongest year in company history and setting a foundation for continued growth in 2026.
Surpassed 110,000 paying subscribers for the Owlet360 subscription service, with strong sequential growth in MRR, attach rate, and retention, and expanded internationally with new regulatory clearances in India and Israel.
Launched the AI-enabled Dream Sight camera and expanded the product suite, including the Owlet360 subscription service, and announced a strategic AI partnership to enhance pediatric health data insights.
Strengthened capital structure and balance sheet through a warrant exchange and $34.5 million equity offering, supporting cash flow independence and growth investments.
Transitioned into a comprehensive pediatric health, safety, and sleep platform, leveraging AI-enabled products and a growing data ecosystem.
Financial highlights
FY2025 revenue reached $105.7 million, up 35.4% year-over-year; Q4 2025 revenue was $26.6 million, up 29.6%.
FY2025 gross profit was $53.5 million with a record 50.6% gross margin; Q4 gross margin was 47.6%, impacted by tariffs.
FY2025 adjusted EBITDA was $2.0 million, a $3.8 million improvement over FY2024; Q4 adjusted EBITDA was $0.1 million.
FY2025 operating loss improved to $8.3 million from $20.2 million; net loss was $39.7 million, including a $26.6 million non-cash warrant liability adjustment.
Cash and cash equivalents at year-end were $35.5 million, with total liquidity of $45.5 million.
Outlook and guidance
FY2026 revenue guidance is $126–$130 million (19–23% growth), gross margin 49–52%, adjusted EBITDA $3–$5 million (50–150% growth).
Q1 2026 revenue expected at $20–$21 million, gross margin 50–52%, adjusted EBITDA -$2.5 to -$1.5 million.
Guidance includes continued tariff impacts and assumes no material contribution from new countries or telehealth, which are considered upside.
Latest events from Owlet
- Subscription growth, telehealth launch, and AI-driven efficiency drive profitability and focus.OWLT
46th Annual William Blair Growth Stock Conference3 Jun 2026 - Subscription and AI-driven health insights fuel growth, with FDA clearance as a key differentiator.OWLT
TD Cowen 10th Annual Future of the Consumer Conference2 Jun 2026 - Q1 2026 revenue up 6.4% to $22.5M, with record subscriptions and improved margins.OWLT
Q1 202611 May 2026 - Record revenue and FDA-cleared status drive growth in pediatric health monitoring.OWLT
Investor presentation1 Apr 2026 - Up to 9.6 million shares registered for resale by major holders; no proceeds to the company.OWLT
Registration Filing10 Mar 2026 - Q1 revenue up 43% with record margin, breakeven EBITDA, and raised guidance amid ongoing risks.OWLT
Q1 20253 Feb 2026 - Dual FDA clearances and strong retail momentum position the company for rapid growth and margin expansion.OWLT
TD Cowen’s 8th Annual Future of the Consumer Conference1 Feb 2026 - Q2 revenue up 58% to $20.7M, gross margin 50%, but going concern risk remains.OWLT
Q2 20241 Feb 2026 - Q3 revenue up 141% to $22.1M, record margin, positive EBITDA, but liquidity risks remain.OWLT
Q3 202414 Jan 2026